Mylan and Pfizer Announce Appointment of Viatris Chief Financial Officer
Pfizer's Upjohn Division CFO Sanjeev Narula selected for leadership role at combined company HERTFORDSHIRE, England and PITTSBURGH and NEW YORK, Feb. 27, 2020 -- (Healthcare Sales & Marketing Network) -- Mylan N.V. (NASDAQ: MYL) and Pfizer (NYSE: PFE) ... Biopharmaceuticals, Mergers & Acquisitions, Personnel Mylan, Pfizer, Upjohn, Viatris (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 27, 2020 Category: Pharmaceuticals Source Type: news

A new strategy to prevent the most aggressive tumors from generating resistance to chemotherapy
(Centro Nacional de Investigaciones Oncol ó gicas (CNIO)) One of the most frequent problems when treating cancer is that the tumors develop resistance to therapies. This is especially relevant in patients with aggressive diseases. A study led by the Spanish National Cancer Research Centre (CNIO) in collaboration with the Weill Cornell Medicine Center and Pfizer Inc. (United States) proposes a novel combined approach to avoid pancreatic cancer resistance to chemotherapy, and thus achieve that the treatments eliminate these tumor cells effectively. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 27, 2020 Category: Cancer & Oncology Source Type: news

Companies in pharmaceutical supply chain develop system to track counterfeit drugs
Some of the industry's largest pharmaceutical companies, including Pfizer Inc and Eli Lilly and Co , have developed a blockchain-based system to track prescription drugs across the supply chain to better halt the flow of counterfeit medicines, company officials said on Friday. (Source: Reuters: Health)
Source: Reuters: Health - February 21, 2020 Category: Consumer Health News Tags: healthNews Source Type: news

Pfizer Vaccines launches global Centers of Excellence Network
Pfizer Inc. (NYSE: PFE) announced today the launch of its Vaccines Division's Centers of Excellence Network, a global program of collaborations with academic institutions to conduct real-world epidemiologic research to accurately identify and measure the burden of specific vaccine-preventable diseases and potentially evaluate vaccine effectiveness affecting adults. (Source: World Pharma News)
Source: World Pharma News - January 23, 2020 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

Pfizer's $225K Price for Heart Drug Tafamidis Slammed Pfizer's $225K Price for Heart Drug Tafamidis Slammed
The current price hinders access for those most likely to benefit and slows clinical advances in the management of ATTR-CM, a'not-so-rare'condition, experts say.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - January 16, 2020 Category: Cardiology Tags: Cardiology News Source Type: news

Insilico collaborates with Pfizer on novel data and AI system for target discovery
(InSilico Medicine) Insilico Medicine has entered into a research collaboration with Pfizer to utilize Insilico's machine learning technology and proprietary Pandomics Discovery Platform with the aim of identifying real-world evidence for potential therapeutic targets implicated in a variety of diseases. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - January 14, 2020 Category: Biology Source Type: news

Biogen to buy early-stage potential Alzheimer's, Parkinson's treatment from Pfizer
Biogen Inc said on Monday it has agreed to buy an early-stage experimental treatment from Pfizer Inc that it aims to test in patients with Alzheimer's and Parkinson's disease. (Source: Reuters: Health)
Source: Reuters: Health - January 13, 2020 Category: Consumer Health News Tags: healthNews Source Type: news

Scripps Acquires Pfizer's Massive Microbial Library
The East Coast campus of the research institute received shipments of freeze-dried or frozen samples of more than 210,000 microbial strains, which scientists plan to mine for potentially useful... (Source: The Scientist)
Source: The Scientist - January 9, 2020 Category: Science Tags: News & Opinion Source Type: news

Pfizer and other drugmakers start 2020 with price rises
Average 6% increase is less than in previous years as industry faces political pressure (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - January 3, 2020 Category: Pharmaceuticals Source Type: news

Drugmakers From Pfizer to GSK to Hike U.S. Prices on Over 200 Drugs Drugmakers From Pfizer to GSK to Hike U.S. Prices on Over 200 Drugs
Drugmakers including Pfizer Inc, GlaxoSmithKline PLC and Sanofi SA are planning to hike prices on more than 200 drugs in the United States on Wednesday, according to drugmakers and data analyzed by healthcare research firm 3 Axis Advisors.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 3, 2020 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Exclusive: Drugmakers from Pfizer to GSK to hike U.S. prices on over 200 drugs
Drugmakers including Pfizer Inc , GlaxoSmithKline PLC and Sanofi SA are planning to hike U.S. list prices on more than 200 drugs in the United States on Wednesday, according to drugmakers and data analyzed by healthcare research firm 3 Axis Advisors. (Source: Reuters: Health)
Source: Reuters: Health - January 1, 2020 Category: Consumer Health News Tags: healthNews Source Type: news

Invest in MSLs to reap bigger gains
  If authenticity, data analysis and good customer rapport are the superpowers pharma needs most today, MSLs are the superheroes most able to wield them.  As the MSL ’s role continues to evolve from a supporting to a far more strategic one, pharma companies have much to gain from getting the most from this ever more important set of colleagues. Pharma therefore needs to invest in them and build MSLs ’ skills and knowledge in new areas, helping them adapt to new ways of interacting and use new technologies that can magnify their impact, says Emma Booth, Director, Medical Capabilities, EU Medical...
Source: EyeForPharma - December 31, 2019 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news

China approves home-grown vaccines, offering alternative to global drugmakers' products
China has approved a pneumonia vaccine developed by Chinese drugmaker Walvax Biotechnology's unit, its National Medical Products Administration said in a notice on Tuesday, offering an alternative to one of Pfizer's best-selling products Prevnar 13. (Source: Reuters: Health)
Source: Reuters: Health - December 31, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

FDA approves first generic of Bristol-Myers, Pfizer's blood thinner Eliquis
The U.S. Food and Drug Administration said on Monday it has approved the first generic version of Bristol-Myers Squibb Co and Pfizer Inc's blood thinner Eliquis. (Source: Reuters: Health)
Source: Reuters: Health - December 23, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Theravance Biopharma and Pfizer Inc. enter global license agreement for skin-targeted, locally-acting pan-Janus kinase (JAK) inhibitor program
Theravance Biopharma Ireland Limited, a subsidiary of Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") and Pfizer Inc. (NYSE: PFE) ("Pfizer") today announced that the companies have entered into a global license agreement for Theravance Biopharma's preclinical program for skin-targeted, locally-acting pan-Janus kinase (JAK) inhibitors that can be rapidly metabolized. (Source: World Pharma News)
Source: World Pharma News - December 23, 2019 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

No difference in results when surgeries are performed by U.S.- or foreign-trained surgeons
FINDINGSA UCLA-led research team analyzed the outcomes of nearly 634,000 common surgical procedures performed in the U.S. between 2011 and 2014 and found that there were no differences in the results of those surgeries based on whether the surgeons had been trained at U.S. medical schools or medical schools outside of the U.S.BACKGROUNDAbout 15% of surgeons practicing in the U.S. received their training at foreign medical schools. Data comparing outcomes for surgeries performed by U.S.-trained surgeons versus those of foreign-trained surgeons has been limited.METHODThe researchers analyzed data from nearly 634,000 Medicare...
Source: UCLA Newsroom: Health Sciences - December 20, 2019 Category: Universities & Medical Training Source Type: news

Company led drug alert – Paclitaxel 6 mg/ml concentrate for solution for infusion (25ml vials)
Hospira UK Limited (Pfizer) is recalling specific batches... (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - December 19, 2019 Category: Drugs & Pharmacology Source Type: news

Pfizer and Mylan Announce Two Future Viatris Board Members
Ian Read and James Kilts offer strong experience to support long-term value creation NEW YORK, Dec. 18, 2019 -- (Healthcare Sales & Marketing Network) -- Pfizer Inc. (NYSE: PFE) and Mylan N.V. (NASDAQ: MYL) today announced that Ian Read and James Kilts... Biopharmaceuticals, Mergers & Acquisitions, Personnel Mylan, Upjohn, Pfizer, Viatris (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 18, 2019 Category: Pharmaceuticals Source Type: news

Mylan, Pfizer name board members to new company
Two new board members have been named to Viatris, the company that will be formed after the merger of Mylan NV (NYSE: MYL) and Upjohn. Both of the pending board members are from Pfizer Inc. (NYSE: PFE), which owns Upjohn: Ian Read is the executive chairman of Pfizer, and had been president and CEO and chairman and CEO before that. James Kilts, founding partner of private equity firm Centerview Capital Holdings LLC, has been a boa rd member of Pfizer since 2007. Read and Kilts were named to the board… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 18, 2019 Category: Pharmaceuticals Authors: Paul J. Gough Source Type: news

Colorado life science companies brought in more than $12 billion in 2019
Colorado life sciences companies raised a combined $12.1 billion in 2019, thanks to the record-breaking acquisition of Boulder-based Array BioPharma by Pfizer (NYSE: PFE) for $11.4 billion. Without that massive acquisition, Colorado biotech still managed to raise $750 million through state and federal grants, financing rounds and other acquisitions, according to the Colorado Bioscience Association, which released the financial roundup on Dec. 17. Some of the highlights included Clo vis Oncology,… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 17, 2019 Category: Pharmaceuticals Authors: Jensen Werley Source Type: news

Colorado life science companies brought in more than $12 billion in 2019
Colorado life sciences companies raised a combined $12.1 billion in 2019, thanks to the record-breaking acquisition of Boulder-based Array BioPharma by Pfizer (NYSE: PFE) for $11.4 billion. Without that massive acquisition, Colorado biotech still managed to raise $750 million through state and federal grants, financing rounds and other acquisitions, according to the Colorado Bioscience Association, which released the financial roundup on Dec. 17. Some of the highlights included Clo vis Oncology,… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 17, 2019 Category: Biotechnology Authors: Jensen Werley Source Type: news

Pfizer wins FDA approval for 'first and only' oral treatment for prostate cancer drug
Pfizer Inc. confirmed that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application to treat prostate cancer. The New York-based pharma giant, which opened Tuesday morning at $39.46 a share, created the new cancer drug with Japan-based Astellas Pharma Inc. The treatment, Xtandi, helps patients with metastatic hormone-sensitive prostate cancer (mCSPC). This type of prostate cancer spreads to other parts o f the body. In 2019, it is estimated that just over 40,000… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 17, 2019 Category: Biotechnology Authors: Anthony Noto Source Type: news

EMA Panel Backs Adalimumab Biosimilar Amsparity EMA Panel Backs Adalimumab Biosimilar Amsparity
The CHMP has recommended approval of Pfizer's adalimumab biosimilar (Amsparity) for treatment of certain inflammatory and autoimmune disorders in adults and children.International Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - December 16, 2019 Category: Drugs & Pharmacology Tags: Rheumatology News Alert Source Type: news

FDA Approves Xtandi (enzalutamide) for the Treatment of Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
NEW YORK& TOKYO--(BUSINESS WIRE)--December 16, 2019 -- Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D.,“Astellas”) announced today that the U.S. Food and Drug Administration... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 16, 2019 Category: Drugs & Pharmacology Source Type: news

Pfizer's rare disease drug gets EMA's positive recommendation
Pfizer Inc said on Friday the European Medicines Agency granted the company a positive recommendation for approval of its treatment for a rare disorder that occurs in patients with cardiomyopathy. (Source: Reuters: Health)
Source: Reuters: Health - December 13, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

FDA Approves Xeljanz XR (tofacitinib) Extended-Release Tablets for the Treatment of Ulcerative Colitis
December 12, 2019 - Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved Xeljanz XR (tofacitinib) extended-release 11 mg and 22 mg tablets for the once-daily treatment of adult patients with moderately... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 12, 2019 Category: Drugs & Pharmacology Source Type: news

ViiV Healthcare submits New Drug Application to the FDA for Fostemsavir, an Investigational, First-in-Class Attachment Inhibitor for the Treatment of HIV in Adults with Few Treatment Options Available
London, 5 December 2019 – ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today completed submission of a New Drug Application (NDA) to the US Food and Drug... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - December 5, 2019 Category: Drugs & Pharmacology Source Type: news

John Halamka heading to Mayo Clinic, Google snipes Facebook health project manager and more digital health hires
Also: Cognoa announces new CFO; Pfizer vets find new roles at Aetion; Senate HELP Committee votes FDA commissioner nominee forward. (Source: mobihealthnews)
Source: mobihealthnews - December 4, 2019 Category: Information Technology Source Type: news

Africa: Gavi Must Stop Giving Millions in Subsidies to Pfizer and Gsk for Pneumonia Vaccine
[MSF] New Delhi/New York -Gavi, the Vaccine Alliance should immediately stop giving millions of dollars in financial incentives to pharmaceutical companies Pfizer and GlaxoSmithKline (GSK) for the pneumococcal conjugate vaccine (PCV), said the international humanitarian organization Doctors Without Borders/M édecins Sans Frontières (MSF) ahead of the group's board meeting in New Delhi, India on December 4 and 5. Instead, Gavi should use the remaining US $262 million of the US $1.5 billion subsidy fund to support the ro (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - December 4, 2019 Category: African Health Source Type: news

Pfizer, Novartis Lead Pharma Spending Spree on Gene Therapy Production Pfizer, Novartis Lead Pharma Spending Spree on Gene Therapy Production
Eleven drugmakers led by Pfizer and Novartis have set aside a combined $2 billion to invest in gene therapy manufacturing since 2018, according to a Reuters analysis, in a drive to better control production of the world's priciest medicines.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - December 3, 2019 Category: Pathology Tags: Internal Medicine News Source Type: news

FDA approves Pfizer's biosimilar, ABRILADA ™ (adalimumab-afzb) for multiple inflammatory conditions
Pfizer Inc. (NYSE: PFE) announced the United States (U.S.) Food and Drug Administration (FDA) has approved ABRILADA™ (adalimumab-afzb), as a biosimilar to Humira® (adalimumab),(1) for the treatment of certain patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, ulcerative colitis and plaque psoriasis.(2) (Source: World Pharma News)
Source: World Pharma News - December 2, 2019 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

UK regulator seeks to reinstate £90m fine against Pfizer and Flynn
CMA appeals against decision to overturn penalty for 2,600% price rise of epilepsy drug (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - November 28, 2019 Category: Pharmaceuticals Source Type: news

Pfizer, Novartis lead $2 billion spending spree on gene therapy production
Eleven drugmakers led by Pfizer and Novartis have set aside a combined $2 billion to invest in gene therapy manufacturing since 2018, according to a Reuters analysis, in a drive to better control production of the world's priciest medicines. (Source: Reuters: Health)
Source: Reuters: Health - November 27, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

The online health trends pharma should be tapping into
Each year digital folk all over the world look to the Internet Trends report, delivered by Bond Capital founder Mary Meeker, for a summary of the most important emerging online technologies and consumer behaviours.    The 2019 report underlines the strength of some trends familiar to pharma and points to some unsettling implications for the industry if it cannot respond appropriately. Along with some general online trends - the growing consumption of images and video, the rise of the podcast and the ongoing spread of Amazon Echo - the report highlights some important consumer healthcare trends.  Perhaps th...
Source: EyeForPharma - November 20, 2019 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news

Pfizer nabs FDA approval for Humira biosim
Abrilada is the fifth Humira biosimilar approved in the U.S. and will join generics from Mylan, Samsung Bioepis and Sandoz when AbbVie's blockbuster has its patent expire in 2023. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - November 19, 2019 Category: Pharmaceuticals Source Type: news

FDA Approves Abrilada (adalimumab-afzb), a Biosimilar to Humira
November 18, 2019 - Pfizer Inc. (NYSE: PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) has approved Abrilada™ (adalimumab-afzb), as a biosimilar to Humira® (adalimumab),1 for the treatment of certain... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 18, 2019 Category: Drugs & Pharmacology Source Type: news

Bristol-Myers Squibb and Pfizer announce randomized, controlled trial to evaluate the effect of atrial fibrillation screening on health outcomes in older individuals
The Bristol-Myers Squibb-Pfizer Alliance today announced the initiation of a new randomized, controlled study, GUARD-AF (ReducinG stroke by screening for UndiAgnosed atRial fibrillation in elderly inDividuals). The study seeks to determine if earlier detection of atrial fibrillation (AFib) through screening in previously undiagnosed men and women at least 70 years of age in the U.S. ultimately impacts the rate of stroke, compared to usual standard medical care. (Source: World Pharma News)
Source: World Pharma News - November 15, 2019 Category: Pharmaceuticals Tags: Featured Bristol-Myers Squibb Business and Industry Source Type: news

Taking the plunge into digital
There are so many opportunities for medical affairs to harness the potential of digital tools it ’s hard to know where to start.  Virtual meetings, cloud-based data sharing and mass intelligence gathering on patients and HCPs are some of the most obvious opportunities. Multiple online, social and other media meanwhile can transform the ability of medical affairs to help healthcare providers and patients find the information they need, when they need it, in the form they need it.  But these are early days, and it ’s hardly controversial to say that medical affairs is still generally only taking baby ...
Source: EyeForPharma - November 13, 2019 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news

Mylan and Pfizer announce Viatris as the new company name in the planned Mylan-Upjohn combination
HERTFORDSHIRE, England & PITTSBURGH & Mylan N.V. (NASDAQ: MYL) and Pfizer Inc. (NYSE: PFE) announced that the name of the new company to be formed by the planned combination of Mylan and Upjohn, a division of Pfizer, will be Viatris (pronounced 'viǝ-trīs). (Source: World Pharma News)
Source: World Pharma News - November 13, 2019 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

Mylan and Upjohn announce name of combined company
The new company that will be created when Mylan and Upjohn combine has a name. On Tuesday, Mylan and Pfizer (of which Upjohn is a division of) announced that the new company will be called Viatris. According to a release, the name is derived from Latin and means, roughly, "a path to three." The name is supposed to embody the new company's goal of providing a path to three c ore goals: expanding access to medicines, leading by innovating to meet patient need and being a trusted partner for the healthcare… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - November 12, 2019 Category: Pharmaceuticals Authors: Mike Larson Source Type: news

Mylan and Upjohn announce name of combined company
The new company that will be created when Mylan and Upjohn combine has a name. On Tuesday, Mylan and Pfizer (of which Upjohn is a division of) announced that the new company will be called Viatris. According to a release, the name is derived from Latin and means, roughly, "a path to three." The name is supposed to embody the new company's goal of providing a path to three c ore goals: expanding access to medicines, leading by innovating to meet patient need and being a trusted partner for the healthcare… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - November 12, 2019 Category: Biotechnology Authors: Mike Larson Source Type: news

Many take anticoagulants and OTC supplements, which poses risk
FINDINGSNearly 98% percent of people prescribed direct-acting oral anticoagulants such as apixaban also used  over-the-counter products. Of those, 33% took at least one such product that, in combination with the anticoagulants, could cause dangerous internal bleeding. People taking these medications largely lacked knowledge of some potentially serious interactions.BACKGROUNDDirect-acting oral anticoagulants are the drug of choice for stroke prevention in patients with atrial fibrillation, which occurs most frequently in older patients. Apixaban is one of the most frequently prescribed. However, most people prescribed ...
Source: UCLA Newsroom: Health Sciences - November 1, 2019 Category: Universities & Medical Training Source Type: news

European agency highlights blood clot risks from Pfizer's arthritis drug
Pfizer Inc's rheumatoid arthritis drug Xeljanz could increase the risk of blood clots in the lungs and in deep veins, the European Medicines Agency (EMA) said on Thursday. (Source: Reuters: Health)
Source: Reuters: Health - October 31, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

U.S. Blames Drug Shortages on Low Prices and a ‘Broken Marketplace’
A government task force suggested that providers pay more for lifesaving generics and that drug makers receive quality ratings. (Source: NYT Health)
Source: NYT Health - October 30, 2019 Category: Consumer Health News Authors: Roni Caryn Rabin Tags: your-feed-science Shortages Drugs (Pharmaceuticals) Children and Childhood Cancer Generic Brands and Products Food and Drug Administration Pfizer Inc Source Type: news

Pfizer and Merck raise guidance on strong China growth
Rosier results come as US drugmakers face pressure on prices in domestic market (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - October 29, 2019 Category: Pharmaceuticals Source Type: news

Pfizer results boosted by innovative drugs and EM growth
Pharmaceutical company delivers rosier guidance as it focuses on branded drugs (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - October 29, 2019 Category: Pharmaceuticals Source Type: news

OPKO and Pfizer announce positive Phase 3 top-line results for somatrogon
OPKO Health Inc. (NASDAQ: OPK) and Pfizer Inc. (NYSE: PFE) announced that the global Phase 3 trial evaluating somatrogon dosed once-weekly in pre-pubertal children with growth hormone deficiency (GHD) met its primary endpoint of non-inferiority to daily GENOTROPIN® (somatropin) for injection, as measured by annual height velocity at 12 months. (Source: World Pharma News)
Source: World Pharma News - October 24, 2019 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

More Children ’s Cancer Drug Coming, Drugmaker Says
The drug’s only maker, Pfizer, says relief may be coming soon. In a letter dated Oct. 18, Pfizer said the next delivery of the drug is expected in late October and will meet current patient needs for the rest of the year. (Source: WebMD Health)
Source: WebMD Health - October 23, 2019 Category: Consumer Health News Source Type: news

Class 2 medicines recall: Sayana Press 104mg/0.65ml
Pfizer Ltd is recalling certain batches of Sayana Press for subcutaneous injection. (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - October 23, 2019 Category: Drugs & Pharmacology Source Type: news

Company-led drug alert – docetaxel injection 80mg /8ml
Pfizer UK Limited is recalling certain batches of docetaxel injection 80mg /8ml. (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - October 22, 2019 Category: Drugs & Pharmacology Source Type: news